604 related articles for article (PubMed ID: 19780621)
1. Ruthenium(II) arene anticancer complexes with redox-active diamine ligands.
Bugarcic T; Habtemariam A; Deeth RJ; Fabbiani FP; Parsons S; Sadler PJ
Inorg Chem; 2009 Oct; 48(19):9444-53. PubMed ID: 19780621
[TBL] [Abstract][Full Text] [Related]
2. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
[TBL] [Abstract][Full Text] [Related]
3. Chlorido-, aqua-, 9-ethylguanine- and 9-ethyladenine-adducts of cytotoxic ruthenium arene complexes containing O,O-chelating ligands.
Melchart M; Habtemariam A; Parsons S; Sadler PJ
J Inorg Biochem; 2007 Nov; 101(11-12):1903-12. PubMed ID: 17582501
[TBL] [Abstract][Full Text] [Related]
4. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
5. Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.
Betanzos-Lara S; Novakova O; Deeth RJ; Pizarro AM; Clarkson GJ; Liskova B; Brabec V; Sadler PJ; Habtemariam A
J Biol Inorg Chem; 2012 Oct; 17(7):1033-51. PubMed ID: 22791215
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
[TBL] [Abstract][Full Text] [Related]
7. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
8. Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts.
Chen H; Parkinson JA; Parsons S; Coxall RA; Gould RO; Sadler PJ
J Am Chem Soc; 2002 Mar; 124(12):3064-82. PubMed ID: 11902898
[TBL] [Abstract][Full Text] [Related]
9. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.
Peacock AF; Habtemariam A; Moggach SA; Prescimone A; Parsons S; Sadler PJ
Inorg Chem; 2007 May; 46(10):4049-59. PubMed ID: 17441712
[TBL] [Abstract][Full Text] [Related]
10. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
Peacock AF; Parsons S; Sadler PJ
J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and intramolecular and interionic structural characterization of half-sandwich (arene)ruthenium(II) derivatives of bis(pyrazolyl)alkanes.
Marchetti F; Pettinari C; Pettinari R; Cerquetella A; Di Nicola C; Macchioni A; Zuccaccia D; Monari M; Piccinelli F
Inorg Chem; 2008 Dec; 47(24):11593-603. PubMed ID: 18998632
[TBL] [Abstract][Full Text] [Related]
12. Bifunctional amine-tethered ruthenium(II) arene complexes form monofunctional adducts on DNA.
Melchart M; Habtemariam A; Novakova O; Moggach SA; Fabbiani FP; Parsons S; Brabec V; Sadler PJ
Inorg Chem; 2007 Oct; 46(21):8950-62. PubMed ID: 17850143
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts.
Wang F; Chen H; Parsons S; Oswald ID; Davidson JE; Sadler PJ
Chemistry; 2003 Dec; 9(23):5810-20. PubMed ID: 14673852
[TBL] [Abstract][Full Text] [Related]
14. Ruthenium(II)-arene complexes with functionalized pyridines: synthesis, characterization and cytotoxic activity.
Grgurić-Sipka S; Ivanović I; Rakić G; Todorović N; Gligorijević N; Radulović S; Arion VB; Keppler BK; Tesić ZLj
Eur J Med Chem; 2010 Mar; 45(3):1051-8. PubMed ID: 20053483
[TBL] [Abstract][Full Text] [Related]
15. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives.
van Rijt SH; Peacock AF; Johnstone RD; Parsons S; Sadler PJ
Inorg Chem; 2009 Feb; 48(4):1753-62. PubMed ID: 19146436
[TBL] [Abstract][Full Text] [Related]
16. The remarkable reactivity of high oxidation state ruthenium and osmium polypyridyl complexes.
Meyer TJ; Huynh MH
Inorg Chem; 2003 Dec; 42(25):8140-60. PubMed ID: 14658865
[TBL] [Abstract][Full Text] [Related]
17. Hydrolytic behaviour and chloride ion binding capability of [Ru(η6-p-cym)(H2O)3]2+: a solution equilibrium study.
Bíró L; Farkas E; Buglyó P
Dalton Trans; 2012 Jan; 41(1):285-91. PubMed ID: 22051630
[TBL] [Abstract][Full Text] [Related]
18. Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.
Cini R; Tamasi G; Defazio S; Corsini M; Zanello P; Messori L; Marcon G; Piccioli F; Orioli P
Inorg Chem; 2003 Dec; 42(24):8038-52. PubMed ID: 14632524
[TBL] [Abstract][Full Text] [Related]
19. Osmium(II) and ruthenium(II) arene maltolato complexes: rapid hydrolysis and nucleobase binding.
Peacock AF; Melchart M; Deeth RJ; Habtemariam A; Parsons S; Sadler PJ
Chemistry; 2007; 13(9):2601-13. PubMed ID: 17200926
[TBL] [Abstract][Full Text] [Related]
20. Switching between kappa(2) and kappa(3) bis(pyrazol-1-yl)acetate ligands by tuning reaction conditions: synthesis, spectral, electrochemical, structural, and theoretical studies on arene-Ru(II) derivatives of bis(azol-1-yl)acetate ligands.
Marchetti F; Pettinari C; Cerquetella A; Cingolani A; Pettinari R; Monari M; Wanke R; Kuznetsov ML; Pombeiro AJ
Inorg Chem; 2009 Jul; 48(13):6096-108. PubMed ID: 19507885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
